INVO Bioscience Appoints Andrea Goren as Chief Financial Officer

Bioscience Appoints Andrea Goren as Chief Financial Officer

Florida - June 15, 2021 - INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the

world's only in vivo Intravaginal Culture System (IVC), INVOcell , an effective and affordable treatment for patients diagnosed

with infertility, today announced the appointment of Andrea Goren as the Company's chief financial officer.

a career approaching 27 years, Mr. Goren has extensive experience in numerous financial functions, including service as a public company

CFO, company director, capital raising activities as well as mergers and acquisition experience. Mr. Goren has served as managing director

and CFO of Phoenix Group, a New York City-based private equity firm specializing in micro-cap and nano-cap public companies. He served

as vice president of Shamrock Group, the Roy Disney family private investment firm in London; and was a director at New York City-based

Madison Capital Group, a corporate advisory firm focused on U.S. / European Union cross border transactions. Mr. Goren holds a Bachelor

of Arts degree from Connecticut College in New London, Connecticut, and an MBA from the Columbia Business School in New York City.

Shum, CEO of INVO Bioscience, said, "We are pleased to appoint a financial executive the caliber of Andrea Goren as chief financial

officer of INVO Bioscience. Andrea has been serving INVO over the past year in a consulting capacity and thus is familiar with the operations

of the company, including many within the finance function. As he takes over as our permanent CFO, he will continue to interface with

our current outside CFO consulting firm to assure a seamless transition. His well-rounded skill set will benefit INVO as we continue

to successfully execute on our strategic business plan, including the operational launch of our various company-owned INVO clinics set

for the second half of this year."

Goren commented, "I am pleased to be joining INVO Bioscience in a full-time capacity as the chief financial officer. Having consulted

with the company over the past year, I am well aware of the opportunity ahead for us to disrupt the fertility market through our revolutionary

INVOcell device. I look forward to working with Steve and the team to further advance our INVO clinic strategy, and further adoption

of the solution across globe."

are a medical device company focused on creating simplified, lower-cost treatments for patients diagnosed with infertility. Our solution,

the INVO Procedure, is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience.

Our lead product, the INVOcell , is a patented medical device used in infertility treatment and is considered an Assisted Reproductive

Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation

of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and

Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal

to lower the cost of care and increase the availability of care. For more information, please visit http://invobioscience.com/

release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section

21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform

Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business

strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations,

as well as statements that include words such as "anticipate," "if," "believe," "plan,"

"estimate," "expect," "intend," "may," "could," "should," "will,"

and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies,

many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated

results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements

include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation

to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

more information, please contact:

Lytham Partners, LLC